Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of NVP-2002 vs Co-administration of Components in Healthy Volunteers
NCT04961905Phase 1Completed
- Sponsor
- NVP Healthcare Co., Ltd.
- Start
- Sep 2022
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of linagliptin and liquid metformin (Aspargo Labs) in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by NVP Healthcare Co., Ltd. Primary endpoints: Maximum Plasma Concentration and Area Under the Curve to the last measurable time point. Started Sep 2022; status: completed.
02
Drugs
linagliptinliquid metformin (Aspargo Labs)
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04961905.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04961905.